Bristol Myers Squibb gained non-exclusive strategic access to Pathos AI's Foundry platform across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programs.

Overview Debates Related claims Topics Sources

552c7ae14Claim

In the Beth Israel trial, consenting patients will interact with MAI-DxO alongside standard medical care to compare its recommendations against decisions made by human doctors.

552c7ae14Claim

MAI-DxO achieves lower estimated costs by judiciously ordering fewer unnecessary medical tests and procedures during sequential patient evaluations.

552c7ae14Claim

Estimated diagnostic work-up costs for MAI-DxO were up to 20% to 50% lower than those designed by human physicians in case simulations.

552c7ae14Claim

Microsoft plans to conduct real-world clinical testing of MAI-DxO with Beth Israel Deaconess Medical Center in Boston to evaluate patient triage in emergency department waiting rooms.

552c7ae14Claim

Pathos AI entered into a strategic collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological conditions.

552c7ae14Claim

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, developed an artificial intelligence tool called iPhenMap to create biological maps of tumors.

552c7ae14Claim

The iPhenMap artificial intelligence tool integrated genetic, metabolic, protein, epigenetic, single-cell, and clinical data from 2,000 patient tumor samples to uncover hidden cellular mechanisms.

552c7ae14Claim

MAI-DxO running on OpenAI's GPT-5 reduced the estimated per-case running cost by about $3,000 on complex cases while raising accuracy from 78.9% to over 83%.

552c7ae14Claim

Bristol Myers Squibb agreed to make fixed payments totaling $137.5 million through 2031 under a Statement of Work with Tempus AI for oncology data and analytic services.

552c7ae14Claim

Essex Partnership University NHS Foundation Trust spent a net total of £4.3 million on Oxevision installation, software fees, and staff training between 2020 and 2025.

552c7ae14Claim

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

552c7ae14Claim

Mass General Brigham radiation oncologist Dr. Raymond Mak stated that the AI facial tools aim to quantify patient physical reserve and frailty to support personalized treatment decisions.

552c7ae14Claim

The FAHR-FaceAge tool estimates a patient's biological age from a photo, while FAHR-FaceSurvival predicts cancer survival outcomes directly from a facial photograph.

552c7ae14Claim

Mass General Brigham researchers developed FAHR-Face, an artificial intelligence foundation model that powers two medical prediction tools called FAHR-FaceAge and FAHR-FaceSurvival.

552c7ae14Claim

The deployment of the AI triage device reduced routine dermatology follow-up appointments from 27% under standard teledermatology down to 12%.

552c7ae14Claim

Use of the AI medical device lowered patient biopsy rates to between 26% and 29%, compared to 43% under standard face-to-face dermatological care.

552c7ae14Claim

Researchers deployed the autonomous AI device in December 2024 and July 2025 at two National Health Service hospital sites in the United Kingdom, managing 8,391 patients.

552c7ae14Claim

An autonomous artificial intelligence device successfully managed 94% of urgent suspected skin cancer referrals during a 16-month study conducted across two U.K. hospital sites.

552c7ae14Claim

Researchers estimated that integrating the AI medical device resulted in a 62% increase in overall clinical capacity for dermatologists.

552c7ae14Claim

In the Beth Israel trial, consenting patients will interact with MAI-DxO alongside standard medical care to compare its recommendations against decisions made by human doctors.

MAI-DxO achieves lower estimated costs by judiciously ordering fewer unnecessary medical tests and procedures during sequential patient evaluations.

Estimated diagnostic work-up costs for MAI-DxO were up to 20% to 50% lower than those designed by human physicians in case simulations.

Microsoft plans to conduct real-world clinical testing of MAI-DxO with Beth Israel Deaconess Medical Center in Boston to evaluate patient triage in emergency department waiting rooms.

Pathos AI entered into a strategic collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological conditions.

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, developed an artificial intelligence tool called iPhenMap to create biological maps of tumors.

The iPhenMap artificial intelligence tool integrated genetic, metabolic, protein, epigenetic, single-cell, and clinical data from 2,000 patient tumor samples to uncover hidden cellular mechanisms.

MAI-DxO running on OpenAI's GPT-5 reduced the estimated per-case running cost by about $3,000 on complex cases while raising accuracy from 78.9% to over 83%.

Bristol Myers Squibb agreed to make fixed payments totaling $137.5 million through 2031 under a Statement of Work with Tempus AI for oncology data and analytic services.

Essex Partnership University NHS Foundation Trust spent a net total of £4.3 million on Oxevision installation, software fees, and staff training between 2020 and 2025.

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

Mass General Brigham radiation oncologist Dr. Raymond Mak stated that the AI facial tools aim to quantify patient physical reserve and frailty to support personalized treatment decisions.

The FAHR-FaceAge tool estimates a patient's biological age from a photo, while FAHR-FaceSurvival predicts cancer survival outcomes directly from a facial photograph.

Mass General Brigham researchers developed FAHR-Face, an artificial intelligence foundation model that powers two medical prediction tools called FAHR-FaceAge and FAHR-FaceSurvival.

The deployment of the AI triage device reduced routine dermatology follow-up appointments from 27% under standard teledermatology down to 12%.

Use of the AI medical device lowered patient biopsy rates to between 26% and 29%, compared to 43% under standard face-to-face dermatological care.

Researchers deployed the autonomous AI device in December 2024 and July 2025 at two National Health Service hospital sites in the United Kingdom, managing 8,391 patients.

An autonomous artificial intelligence device successfully managed 94% of urgent suspected skin cancer referrals during a 16-month study conducted across two U.K. hospital sites.

Researchers estimated that integrating the AI medical device resulted in a 62% increase in overall clinical capacity for dermatologists.

The AI triage device safely discharged 31% and 25% of benign skin cancer cases without clinician review at the two U.K. hospital sites.